Description
Taylor & Francis Pharmacotherapy in Chronic Obstructive Pulmonary Disease 2003 Edition by Bartolome R. Celli
Placing specialists at the cutting-edge of therapeutic and biotechnological research, this reference reviews the extensive array of pharmaceutical options available for the management of patients with COPD. The book considers disease severity, dosing regimens, administration methods, and monitoring procedures, as well as medication-related side-effects for improved lung function, reduction of disease symptoms, and enhanced quality of life. Contributions from world-renowned authorities reflect recent practices, controversies, and procedures in the control of COPD symptoms and detail the development and efficacy of therapies such as anticholinergics, beta adrenergics, and corticosteroids. Table of contents : - The application of clinical assessment to the drug development process: providing evidence of therapeutic benefit in clinical drug development, Steven Kesten and Theodore J. Witek, Jr. Measuring outcomes: physiology; spirometry and lung volumes, GaryT. Ferguson; exercise testing, Denis E. O'Donnell and Katherine Webb; sleep-related breathing disturbances in COPD, Walter T. McNicholas; special tests of flow and resistance, Noe Zamel; gas exchange, R. Rodriguez-Roisin. Laboratory: genetics of COPD,Jian-Qing, Ikuma Kasuga and Peter D. Pare. Health outcomes: dyspnea, Donald A. Mahler; exacerbations, Wedschiza; health status, Paul W. Jones; health resource utilization, Mitchell Friedman. Specific therapy: anticholinergics, Peter J. Barnes; betaadrenergics, Rennard; theophylline and phosphodiesterase inhibitors in COPD, Alicia R. ZuWallack and Richard L. ZuWallack; corticosteroids, Pawels; antioxidants and protease inhibitors, Mario Cazzola and Maria Gabriella Matera; integrated approach topharmacotherapy, Bartolome Celli.